Abstract 17446: Fasting Remnant Cholesterol Levels Predict Incident Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease: The ACCELERATE Trial

Background: Statins reduce LDL-C and cardiovascular risk in patients with atherosclerotic cardiovascular disease (ASCVD). However, in patients treated with statins, it is uncertain whether measures of triglyceride-rich lipoproteins (TRLs) predict risk. Objectives and Methods: This study examined univariate and multivariate relationships of baseline fasting triglyceride or remnant cholesterol levels to the primary outcome (composite endpoint of cardiovascular death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina) in the ACCELERATE trial of 12,092 ASCVD patients randomized to receive evacetrapib or placebo, and followed for a median of 26 months. 97% of patients were on statin therapy. Age, sex, hypertension, current smoking, diabetes, body mass index, and LDL-C were used as covariate. Results: Fasting triglyceride levels were associated with cardiovascular risk only as a univariate [Table]. Remnant cholesterol levels were associated with cardiovascular ris...